Summary: Researchers provide evidence that certain species of human herpesvirus contribute to the development of Alzheimer’s disease. The study reports high levels of human herpesvirus 6A and 7 were found in brain samples showing signs of Alzheimer’s neuropathology. The findings offer hints of the viral mechanisms that could trigger or exacerbate AD.
Source: Arizona State University.
Of the major illnesses facing humanity, Alzheimer’s disease (AD) remains among the most pitiless and confounding. Over a century after its discovery, no effective prevention or treatment exists for this progressive deterioration of brain tissue, memory and identity. With more people living to older ages, there is a growing need to clarify Alzheimer’s disease risk factors and disease mechanisms and use this information to find new ways in which to treat and prevent this terrible disorder.
A first-of-its kind study implicates another culprit in the path to Alzheimer’s disease: the presence of viruses in the brain.
In research appearing in the advanced online edition of the journal Neuron, scientists at the Arizona State University-Banner Neurodegenerative Disease Research Center (NDRC) and their colleagues at the Icahn School of Medicine at Mount Sinai used large data sets from clinically and neuropathologically characterized brain donors and sophisticated “big data” analysis tools to make sense of both the genes that are inherited and those that are preferentially turned on or off in the brains of persons with Alzheimer’s disease. They provide multiple lines of evidence to suggest that certain species of herpesviruses contribute to the development of this disorder.
The new work brings science a step closer to clarifying the mechanisms by which infectious agents may play important roles in the disease. To achieve this, the team capitalized on DNA and RNA sequencing data from 622 brain donors with the clinical and neuropathological features of Alzheimer’s disease and 322 brain donors without the disease–data generated from the NIH-sponsored Accelerated Medicines Partnership for Alzheimer’s Disease (AMP-AD).
The “whole exome” DNA sequencing was used to provide detailed information about each person’s inherited genes. RNA sequencing from several brain regions was used to provide detailed information about the genes that are expressed differently in donors with and without the disease.
Clinical assessments performed before the research participants died provided detailed information about their trajectory of cognitive decline, and neuropathological assessments performed after they died provided relevant neuropathological information, including the severity of amyloid plaques and tangles, the cardinal features of Alzheimer’s disease. Sophisticated computational tools were used to develop a kind of grand unified picture of the viral-AD nexus.
Big challenges, big data
Big data-driven analyses offer a particularly powerful approach for exploring diseases like Alzheimer’s, which involve many interdependent variables acting in concert in profoundly complex systems. In the current study, researchers explore viral presence in 6 key brain regions known to be highly vulnerable to the ravages of AD. (It is now accepted that damaging effects to these areas often precede clinical diagnosis of the disease by several decades.)
The study identifies high levels of human herpesvirus (HHV) 6A and 7 in brain samples showing signs of AD neuropathology, compared with the lower levels found in normal brains. Further, through the careful comparison of large data sets of viral RNA and DNA with networks of human genes associated with AD and signposts of neuropathology, the study offers the first hints of the viral mechanisms that could trigger or exacerbate the disease.
The findings, originally hinted at from samples provided by Translational Genomics (TGen) in Phoenix, were confirmed in the Mount Sinai Brain Bank, and then replicated in samples from the Mayo Clinic Brain Bank, Rush Alzheimer’s Disease Center, and the Banner-Sun Health Research Institute’s Brain and Body Donation Program.
According to Ben Readhead, lead author of the new study, the researchers’ general goal was to discover disease mechanisms, including those that could be targeted by repurposed or investigational drug therapies. “We didn’t go looking for viruses, but viruses sort of screamed out at us,” Readhead said.
Although the study found a number of common viruses in normal aging brains, viral abundance of two key viruses–HHV 6A and 7–was greater in brains stricken with Alzheimer’s.
“We were able to use a range of network biology approaches to tease apart how these viruses may be interacting with human genes we know are relevant to Alzheimer’s,” Readhead said.
Readhead is an assistant research professor in the NDRC, housed at ASU’s Biodesign Institute. Much of the research described in the new study was performed in the laboratory of Joel Dudley, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, associate research professor in the NDRC, and senior author of the paper in Neuron.
The nature and significance of viruses and other pathogens in the brain are currently hot topics in neuroscience, though the exploration is still in its early stages. One of the primary questions is whether such pathogens play an active, causative role in the disease or enter the brain simply as opportunistic passengers, taking advantage of the neural deterioration characteristic of AD.
“Previous studies of viruses and Alzheimer’s have always been very indirect and correlative. But we were able to perform a more sophisticated computational analysis using multiple levels of genomic information measured directly from affected brain tissue. This analysis allowed us to identify how the viruses are directly interacting with or coregulating known Alzheimer’s genes,” says Dudley. “I don’t think we can answer whether herpesviruses are a primary cause of Alzheimer’s disease. But what’s clear is that they’re perturbing and participating in networks that directly underlie Alzheimer’s pathophysiology.”
The new study uses a network biology approach to holistically incorporate molecular, clinical and neuropathological features of AD with viral activity in the brain. Using techniques in bioinformatics, the study integrates high-throughput data into probabilistic networks that are postulated to account for the associations between herpes viruses and the telltale effects of AD.
The networks described suggest that the hallmarks of AD may arise as collateral damage caused by the brain’s response to viral insult. According to the so-called pathogen hypothesis of AD, the brain reacts to infection by engulfing viruses with the protein amyloid beta (Aβ), sequestering the invaders and preventing them from binding with cell surfaces and inserting their viral genetic payload into healthy cells.
As Readhead explains, “a number of viruses looked interesting. We saw a key virus, HHV 6A, regulating the expression of quite a few AD risk genes and genes known to regulate the processing of amyloid, a key ingredient in AD neuropathology.” (Amyloid concentrations form characteristic plaques in the brain. These plaques, along with neurofibrillary tangles formed by another protein, known as tau, are the microscopic brain abnormalities used to diagnosis Alzheimer’s.)
Both HHV 6A, and 7 are common herpesviruses belonging to the genus Roseolovirus. Most people are exposed to them early in life. The likely route of entry for such viruses is through the nasopharyngeal lining. The higher abundance of these viruses in AD-affected brains may initiate an immune cascade leading to deterioration and cell death or act in other ways to promote AD.
The results from human brain tissue were further supplemented by mouse studies. Here, researchers examined the effect of depleting miR155, a small snippet of RNA (or micro RNA) that is an important regulator of the innate and adaptive immune systems. Results showed increased deposition of amyloid plaques in miR155-depleted mice, coupled with behavioral changes. As the authors note, HHV 6A is known to deplete miR155, lending further weight to a viral contribution to AD.
The new research is the fruitful result of close working relationships among researchers from Arizona State University, Banner, Mount Sinai, and other research organizations, as well as public-private partnerships in AMP-AD.
“This study illustrates the promise of leveraging human brain samples, emerging big data analysis methods, converging findings from experimental models, and intensely collaborative approaches in the scientific understanding of Alzheimer’s disease and the discovery of new treatments,” said study co-author Eric Reiman, Executive Director of the Banner Alzheimer’s Institute and University Professor of Neuroscience at Arizona State University. “We are excited about the chance to capitalize on this approach to help in the scientific understanding, treatment and prevention of Alzheimer’s and other neurodegenerative diseases.”
Enemy with a thousand faces
In the meantime, Alzheimer’s continues its devastating trajectory. Among the many challenges facing researchers is the fact that the earliest effects of the disease on vulnerable brain regions occur 20 or 30 years before memory loss, confusion, mood changes and other clinical symptoms appear. Without a cure or effective treatment, AD is expected to strike a new victim in the United States every 33 seconds by mid-century and costs are projected to exceed $1 trillion annually.
The research study does not suggest that Alzheimer’s disease is contagious. But if viruses or other infections are confirmed to have roles in the pathogenesis of Alzheimer’s, it could set the stage for researchers to find novel anti-viral or immune therapies to combat the disease, even before the onset of symptoms.
Additional contributors to the study include: Center for NFL Neurological Care, Department of Neurology, New York; James J. Peters VA Medical Center, New York; Arizona Alzheimer’s Consortium, Phoenix, AZ; Department of Psychiatry, University of Arizona, Tucson, AZ; Banner Alzheimer’s Institute, Phoenix, AZ; Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ; Institute for Systems Biology, Seattle, WA.
Postmortem brain tissue was collected through the NIH-designated NeuroBioBank (NBB) System that contributes to support of the Mount Sinai VA/Alzheimer’s Disease Research Center Brain Bank (AG005138).
The Dudley Laboratory at the Icahn School of Medicine at Mount Sinai has an institutional partnership with Banner-ASU Neurodegenerative Disease Research Center.
Postmortem brain tissue was collected through the NIH-designated NeuroBioBank (NBB) System that contributes to support of the Mount Sinai VA/Alzheimer’s Disease Research Center Brain Bank (AG005138). Dr. Vahram Haroutunian from the Mount Sinai School of Medicine is Director of the NeuroBioBank.
Additional postmortem data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, R01 NS080820, Cure PSP Foundation, and support from Mayo Foundation, U24 NS072026, P30 AG19610, Michael J. Fox Foundation for Parkinson’s Research P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department of Public Health, and the Translational Genomics Research Institute.
Additional work performed in this study was supported by U01 AG046170, R56AG058469, and philanthropic financial support was provided by Katherine Gehl.
Funding: NIH/National Institute on Aging, Accelerated Medicines Partnership for Alzheimer’s Disease, and others funded this study.
Source: Joseph Caspermeyer – Arizona State University
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com images are credited to Shireen Dooling for the Biodesign Institute at ASU.
Original Research: Open access research for “Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus” by Ben Readhead, Jean-Vianney Haure-Mirande, Cory C. Funk, Matthew A. Richards, Paul Shannon, Vahram Haroutunian, Mary Sano, Winnie S. Liang, Noam D. Beckmann, Nathan D. Price, Eric M. Reiman, Eric E. Schadt, Michelle E. Ehrlich, Sam Gandy, and Joel T. Dudley in Neuron. Published June 21 2018.
Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus
•Common viral species frequently detected in normal, aging brain
•Increased HHV-6A and HHV-7 in brains of subjects with Alzheimer’s disease (AD)
•Findings were replicated in two additional, independent cohorts
•Multiscale networks reveal viral regulation of AD risk, and APP processing genes
Investigators have long suspected that pathogenic microbes might contribute to the onset and progression of Alzheimer’s disease (AD) although definitive evidence has not been presented. Whether such findings represent a causal contribution, or reflect opportunistic passengers of neurodegeneration, is also difficult to resolve. We constructed multiscale networks of the late-onset AD-associated virome, integrating genomic, transcriptomic, proteomic, and histopathological data across four brain regions from human post-mortem tissue. We observed increased human herpesvirus 6A (HHV-6A) and human herpesvirus 7 (HHV-7) from subjects with AD compared with controls. These results were replicated in two additional, independent and geographically dispersed cohorts. We observed regulatory relationships linking viral abundance and modulators of APP metabolism, including induction of APBB2, APPBP2, BIN1, BACE1, CLU, PICALM, and PSEN1 by HHV-6A. This study elucidates networks linking molecular, clinical, and neuropathological features with viral activity and is consistent with viral activity constituting a general feature of AD.